Analysis of breast-cancer gene role offers promising target for drugs to stop or slow progression of disease
DALLAS — Oct. 30, 2006 — Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients.
In a study published in this week's issue of the Proceedings of the National Academy of Sciences, the gene, called uPAR, offers a promising target for therapeutic drugs to stop or slow the progression of the disease and could serve as a screening tool for assessing which types of drugs a patient will respond to.
The gene launches a biochemical process in which a molecule called plasmin perforates the membranes of tissues, causing the membranes to break down and allowing the cancer cells to escape into the bloodstream and to adjacent tissues. The result is metastasizing breast cancer. About 20 percent to 25 percent of breast-cancer patients were shown to have uPAR gene amplification, which means they carry too many copies of the gene.
"The uPAR system probably plays a role in metastases in many of the common solid tumors," said Dr. Jonathan Uhr, professor in the Cancer Immunobiology Center and of microbiology and the study's senior author.
While analyzing slides of individual tumor cells — either from the primary tumor or circulating tumor cells — of 72 patients with advanced recurrent breast carcinoma, the UT Southwestern research team discovered how uPAR may work in concert with another known breast cancer gene, HER-2.
The researchers suggest that uPAR may amplify the cancer-causing effects of HER-2.
"This gene, uPAR, is an important oncogene, and that is why we determined whether or not it is amplified," said Dr. Uhr. "Unexpectedly, it is usually amplified in the same tumor cell with HER-2 gene amplification. This has significant implications for treatment with targeting agents. Moreover, we stress the value of individual tumor cell analysis for providing information that cannot be obtained by conventional pathological examination."
Dr. Debu Tripathy, professor of internal medicine, director of the Komen/UT Southwestern Breast Cancer Research Program and a coauthor of the study, said the biochemical process triggered by uPAR, called the urokinase plasminogen activator system, is one of the breast-cancer prognostic factors that has the greatest level of evidence.
"All the work has been on the protein and enzymatic activity and not amplification of the gene, which is a very reliable and easy-to-use diagnostic test called FISH," said Dr. Tripathy. "The other important finding is that HER-2 and uPAR gene amplification tend to co-exist, and this has implications in new strategies to address HER-2-positive breast cancer with drugs that block both HER-2 and urokinase given together."
The study opens a promising avenue to increase the effectiveness of the drug trastuzumab (Herceptin) by adding a second drug seeking to neutralize the uPAR gene.
"One major avenue of investigation would be to develop an antibody that prevents uPAR from binding to a molecule called uPA that can activate uPAR," Dr. Uhr said.
Other UT Soutwestern researchers contributing to the study included: Dr. Songdong Meng, a postdoctoral researcher in the Cancer Immunobiology Center; Dr. Raheela Ashfaq, professor of pathology; Dr. Barbara Haley, professor of internal medicine; Dr. Eugene Frenkel, professor of internal medicine and radiology; Dr. David Euhus, associate professor of surgical oncology; Dr. Marilyn Leitch, professor of surgical oncology; and Nancy Lane, a research scientist, and Jianqiang Wang, research assistant, both in the Cancer Immunobiology Center. Additional research was contributed by the UT M.D. Anderson Cancer Center; Texas Oncology Group; Surgical Associates of Irving-Coppell; Dallas Surgical Group; Abbott Molecular Inc. the Wistar Institute; and Immunicon Corp.
The research was supported by grants from the National Cancer Institute and the Susan G. Komen Breast Cancer Foundation.
The UT Southwestern Harold C. Simmons Comprehensive Cancer Center combines the highest standards of individual care with innovative programs for cancer diagnosis, treatment and prevention based on UT Southwestern' s internationally recognized research coupled with the most sophisticated equipment and advanced technologies available. The expertise of the physicians in the Simmons Cancer Center extends to virtually every cancer in every age group, from breast, urologic, gynecologic, lung, gastrointestinal, head and neck, brain, and skin to lymphomas, leukemia, and bone marrow transplantation.
Visit http://www.utsouthwestern.org/cancercenter to learn more about UT Southwestern’s clinical services in cancer.
UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members — including four active Nobel Prize winners, more than any other medical school in the world — are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
Media Contact: Toni Heinzl
To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews